Metabolic control in diabetic nephropathy;Metabolische kontrolle bei diabetischer nephropathie

Diabetologe

Volumn 2, Issue 5, 2006, Pages 410-418

  Hasslacher, C ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blood pressure adjustment; Diabetic nephropathy; Insulin therapy; Metabolic adjustment; Pharmacokinetics

Indexed keywords

EID: 33748796112     PISSN: 18609716     EISSN: 18609724     Source Type: Journal    
DOI: 10.1007/s11428-006-0074-2     Document Type: Article

References (28)

1. Alvestrand A (1997) Carbohydrate and insulin metabolism in renal failure. Kidney Int [Suppl 62] 52: S-48-S-52
2. Ben-Ami H, Nagachandran R Mendelson A et al. (1999) Drug-induced hypoclycemia coma in 102 diabetic patients. Arch Intern Med 159:281-384
3. Brenner B, Cooper M, Dick de Zeeuw PH et al. (2001) Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephrophathy. N Engl J Med 345:861-869
4. Cersosimo E, Garlick R Ferretti J (1999) Renal glucose production during insulin-induced hypoclycemia in humans. Diabetes 48:262-266
5. Charlesworth JA, Kriketos AD, Jones JE et al. (2005) Insulin resistance and postprandial triglyceride levels in primary renal disease. Metabolism 54:821-828
6. Eckland DA, Danhof M (2000) Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes [Suppl 2] 108:234-242
7. Feld-Rasmussen B, Mathiesen ER, Jensen T et al. (1991) Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34:164-170
8. Gaede P,Vedel Pernille, Parving HH et al. (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353:617-622
9. Lewis E, Hunsiker L, Brain P et al. (1993) The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462
10. Lewis E, Hunsicker L, ClarkeWet al. (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
11. Lindholm L, Ibsen H, Dahlöf B et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention für endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359:1004
12. Hasslacher C, Wittmann W (2003) Schwere Hypoglykämien bei Diabetikern mit eingeschränkter Nierenfunktion. Dtsch Med Wochenschr 128:253-256
13. Hasslacher C, Vogt C, Raupp D et al. (eingereicht) Insulinbedarf bei Typ 1-Diabetikern mit nachlassender Nierenfunktion: Human-Insulin versus Analog-Insulin, zur Publikation eingereicht
14. Jönsson A, Rydberg T, Sterner G et al. (1998) Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429-435
15. Mai-Szu Wu, Chun-Chen Yu, Chih-Wei Yang et al. (1997) Poor pre-dialysis glycaernic control is a predictor of mortality in type 2 diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12:2105-2110
16. Manto A, Cortroneo P, Marra G et al. (1995) Effect of intensive treatment in diabetic nephropathy in patients with type 1 diabetes. Kidney Int 47:231-235
17. Nyberg G, Blohme G, Nordern G (1987) Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30:82-86
18. Rave K, Heise T, Pfützner A et al. (2001) Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 24:886-890
19. Ravid M, Brosh D, Levi Z et al. (1998) Use of en-alapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 128: 982-988
20. Rosenkranz R, Profozic V, Metelko Z et al. (1996) Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39:1617-1624
21. Ruggenenti P, Ilieva A, Bruno S (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951
22. Schumacher S, Abbasi I, Weise D et al. (2001) Single-and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147-152
23. Shichiri M, Kishikawa H, Ohkubo Y et al. (2000) Long-term results of the Kumarmoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care [Suppl 2] 23: B21-B29
24. Svensson M, Yu ZW, Eriksson JW (2002) A small reduction in glomerular filtration is accompanied by insulin resistance in type I diabetes patients with diabetic nephropathy. Eur J Clin Invest 32:100-109
25. The Diabetes Control and Complications Trial Research Group (1996) The absence of a glycemic threshold for the development of long term complications: the perspective of the diabetes control and complications trial. Diabetes 45:1289-1298
26. The Diabetes Control and Complications Trial Research Group/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389
27. Vogt C, Dreyhaupt J, Hasslacher C (eingereicht) Einfluss der nachlassenden Nierenfunktion auf die Insulindosis bei Typ 1 und Typ 2-Diabetikern, zur Publikation eingereicht
28. Warram JH, Scott LJ, Hanna LS et al. (2000) Progression of microalbuminuria to proteinuria in type 1 diabetes; nonlinear relationship with hyperglycemia. Diabetes 49:94-98